The IMPA1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population targeting the IMPA1 gene in the human SK-HEP-1 hepatic adenocarcinoma cell line. This product provides a mixed population of cells with heterogeneous gene-disruption events mediated by CRISPR/Cas9, avoiding clonal selection and thereby preserving a broader genetic representation suitable for studying IMPA1 loss-of-function in a population context. The polyclonal format facilitates robust experimental designs where clonal artifacts are minimized, and it is particularly useful for pathway analysis, drug screening, and functional genomics applications where pooled knockout effects are desired.
SK-HEP-1 cells are an established epithelial cell line derived from the ascites of a patient with liver adenocarcinoma. They are widely employed as a model for hepatocellular carcinoma (HCC) research due to their transformed hepatocyte phenotype and retention of key signaling pathways relevant to hepatic tumorigenesis. The SK-HEP-1 cell line has been extensively utilized in studies of liver cancer cell proliferation, migration, invasion, and drug sensitivity, making it an appropriate host for investigating the role of IMPA1 in HCC pathobiology. The integration of CRISPR/Cas9-mediated IMPA1 disruption into this cell background creates a powerful tool to dissect the gene’s contribution to liver cancer-associated processes.
IMPA1 encodes inositol monophosphatase 1, a magnesium-dependent enzyme that catalyzes the dephosphorylation of inositol monophosphate to myo-inositol, a critical step in the recycling of inositol for phosphatidylinositol (PI) resynthesis. This reaction lies at the intersection of the phosphatidylinositol signaling system and inositol phosphate metabolism. Upstream, IMPA1 is regulated by Gq-coupled receptor activation and epidermal growth factor receptor (EGFR) signaling, and it is a well-known molecular target of lithium, which acts as an uncompetitive inhibitor. Downstream, IMPA1 activity sustains cellular myo-inositol pools, facilitating the resynthesis of PI(4,5)P2 and maintaining phosphoinositide-dependent signaling cascades, including phospholipase C (PLC)-mediated generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), which in turn modulate protein kinase C (PKC) signaling and calcium flux. Disruption of IMPA1 thus impairs inositol homeostasis, leading to altered PI signaling and potential downstream effects on cell growth and survival pathways.
In the context of hepatocellular carcinoma, IMPA1 knockout in SK-HEP-1 cells provides a unique model to study the intersection of inositol metabolism and liver cancer biology. Given that PI signaling and PKC pathways are frequently dysregulated in HCC, loss of IMPA1 may sensitize cells to lithium-mediated effects or alter apoptotic responses. Furthermore, because IMPA1 is implicated in bipolar disorder and lithium-responsive neuropsychiatric conditions, this model permits exploration of lithium’s anticancer mechanisms in a hepatic tumor environment. The polyclonal IMPA1 knockout population allows researchers to assess the functional consequences of IMPA1 disruption on oncogenic phenotypes such as proliferation, migration, and invasion, while avoiding clonal variability that could confound interpretation.
Typical research applications of this product include investigation of inositol metabolism in hepatocellular carcinoma, PI signaling pathway analysis, drug sensitivity screening (particularly lithium and other IMPA1-targeting agents), and functional studies employing phosphoinositide profiling or myo-inositol quantification assays. Experimental readouts may encompass Western blotting and RT-qPCR for IMPA1 expression confirmation, phospho-PKC analysis, calcium imaging, and apoptosis or migration/invasion assays. The polyclonal IMPA1 knockout SK-HEP-1 cells thus serve as a versatile platform for dissecting IMPA1-dependent signaling networks in liver cancer and for evaluating therapeutic strategies targeting inositol-related pathways. For additional technical information or batch-specific details, please contact Ascent Research.
